Wang Y, Mei K, Xiang M F, Li J M, Xie R M
Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan, China.
Eur J Gynaecol Oncol. 2013;34(4):307-10.
To analyze the clinicopathological data of 13 cases of small cell neuroendocrine carcinoma (SCNEC) of the uterine cervix who received treatment at this medical institutions over the past five years with patient survival as the primary endpoint.
The clinicopathologic data of 13 cases were reviewed. Immunohistochemistry was performed using antibodies against synaptophysin and chromogranin A and Ki-67. Survival was analyzed using the Kaplan-Meier method and log-rank tests.
The median age of these patients was 37 years (range 21-62). Immunohistochemistry showed that the positive rate of synaptophysin and chromogranin A was 100% (13/13) and 69.23% (9/13), respectively. The median survival of patients with early-Stage I-II SCNEC of the uterine cervix (17.5 months) was significantly higher than that of patients with advanced stage SCNEC of the uterine cervix (four months) (p < 0.05). There was no local recurrence in all 13 patients. Five patients died of distant metastasis in less than six months.
SCNEC of the uterine cervix is a highly-malignant disease and early-stage patients showed significantly longer survival compared to late-stage patients. Early diagnosis and prompt combination treatment may improve the outcome of patients with SCNEC of the uterine cervix.
分析过去五年在本医疗机构接受治疗的13例宫颈小细胞神经内分泌癌（SCNEC）患者的临床病理资料，以患者生存情况作为主要终点指标。
回顾13例患者的临床病理资料。采用抗突触素、嗜铬粒蛋白A和Ki-67的抗体进行免疫组织化学检测。采用Kaplan-Meier法和对数秩检验分析生存情况。
这些患者的中位年龄为37岁（范围21 - 62岁）。免疫组织化学显示，突触素和嗜铬粒蛋白A的阳性率分别为100%（13/13）和69.23%（9/13）。宫颈I-II期早期SCNEC患者的中位生存期（17.5个月）显著高于宫颈晚期SCNEC患者（4个月）（p < 0.05）。13例患者均无局部复发。5例患者在不到6个月内死于远处转移。
宫颈SCNEC是一种高度恶性疾病，早期患者的生存期明显长于晚期患者。早期诊断并及时进行联合治疗可能改善宫颈SCNEC患者的预后。
